Chemoproteomics in Phenotypic Drug Discovery
Chemoproteomics is a natural complement of phenotypic drug discovery. We examine developments in the area and its future potentials.
Chemoproteomics is a natural complement of phenotypic drug discovery. We examine developments in the area and its future potentials.
PROTACs have been a promising new treatment modality for years – we examine their recent history and innovations that show their potential
Multispecific drugs promise to be one of the big waves of innovation in pharma – we examine the main modalities and their impact.
Highlights from drug launches in February 2022 – including controversy around Ruzurgi, and new orphan drugs.
A summary of the highlights in new drug approvals that happened in January 2022, including new JAKs and therapies for cancer, endocrine disorders and eczema.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings